Samsung BioLogics Inks Manufacturing Deal for Coronavirus Treatment
SEOUL, April 10 (Korea Bizwire) — Samsung BioLogics, a biopharmaceutical unit of South Korea’s Samsung Group, said Friday that it has clinched a US$362 million deal to manufacture a candidate treatment for the novel coronavirus. Under the deal, Samsung BioLogics will start full-scale production of U.S. drug firm Vir Biotechnology’s candidate COVID-19 treatment that is [...]